Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 13,110 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06741020RecruitingPhase 1/Phase 2
Chemo and Immunotherapy before Liver Cancer Surgery
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hangzhou, ZhejiangAges 18–75 - NCT06742411RecruitingPhase 1/Phase 2
Chemo plus immunotherapy and hyperbaric oxygen for advanced stomach cancer
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
Chengdu, SichuanAges 18–75 - NCT06744764Recruiting
Pulsed electromagnetic fields to prevent muscle loss in hospital
This trial tests whether pulsed electromagnetic fields can help prevent muscle loss and weakness in patients with blood cancer who are in the hospital for a long time. It is for patients starting chemotherapy for acute leukemia or getting a stem cell transplant.
Kent RidgeAges 25–99 - NCT06746623Recruiting
Non-endoscopic screening for Barrett's in veterans without reflux
This trial tests a new, non-endoscopic screening method for Barrett's esophagus (a condition that can lead to cancer) in veterans who do not have chronic acid reflux. It aims to find early signs of the condition using a simple swallowable device, potentially avoiding the need for a traditional endoscopy.
Cleveland, OhioAges 40–85 - NCT06748456Recruiting
PSA test use in general practice
This trial tests a program to help doctors use PSA tests based on evidence. It looks at whether a cluster meeting can improve how PSA tests are used in general practice.
CopenhagenAges Any age - NCT06749691RecruitingPhase 2
Liposomal irinotecan and apatinib for extensive-stage small cell lung cancer
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT06751303Recruiting
Patient preferences for ovarian cancer treatment with PARP inhibitors
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
Saskatoon, SAges Any age - NCT06751498Recruiting
Predicting kidney function after partial nephrectomy with AI
This trial uses a special computer model to predict how well your kidneys will work after surgery to remove part of a kidney (partial nephrectomy). It may help doctors plan better care for people with early-stage kidney tumors.
Nanjing, JiangsuAges 18–80 - NCT06751914Recruiting
Vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751940Recruiting
Personalized vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
Nanchang, JiangxiAges 18–70 - NCT06751953Recruiting
Neoantigen vaccine plus standard third-line therapy for colorectal cancer
This study tests a vaccine made from your tumor's unique proteins (neoantigens) combined with a standard third-line therapy for colorectal cancer that has worsened after two previous treatments. The goal is to see if this combination helps control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751966Recruiting
Peptide vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized peptide vaccine (based on your tumor's unique markers) combined with standard third-line therapy for colorectal cancer that has progressed after two prior treatments. The goal is to see if adding the vaccine can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06752239RecruitingPhase 3
Optimizing radiation to protect thyroid in nasopharyngeal cancer
This trial tests a way to adjust radiation therapy to better protect the thyroid gland during treatment for nasopharyngeal carcinoma. It aims to reduce thyroid damage while still effectively treating the cancer.
Nanchang, JiangxiAges 18–70 - NCT06752512Recruiting
Remote temperature monitoring for patients at risk of fever
This trial tests a smartphone app and wearable sensor to track your temperature after leaving the hospital, alerting you or your doctors if a fever develops. It aims to catch fevers early so you can get faster care.
Schenectady, New YorkAges 18 years+ - NCT06753747RecruitingPhase 1/Phase 2
Afatinib and palbociclib for advanced esophageal cancer
This trial tests a combination of two targeted drugs (afatinib and palbociclib) for people with advanced esophageal squamous cell carcinoma that has grown after previous treatment. It is designed for those whose cancer cells have too much of a protein called EGFR.
Chengdu, SichuanAges 18–75 - NCT06754345Recruiting
PET scan study for PD-L1 in cancer patients
This trial uses a special PET scan called 68Ga-NK224 to look for a protein called PD-L1 in tumors. This may help doctors understand your cancer better and find the right treatment for you.
Xiamen, FujianAges 18–90 - NCT06754930RecruitingPhase 1/Phase 2
Study of SHR-1826 combined with other treatments for lung cancer
This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06755762Recruiting
3D blood test for advanced head and neck cancer
This study uses a special 3D culture method to grow and analyze tumor cells from the blood of people with advanced head and neck cancer. It also includes healthy volunteers for comparison, to help researchers understand how these cells behave and improve future detection.
TaoyuanAges 18–80 - NCT06756074RecruitingPhase 2
Surgical glue study for Whipple surgery patients
This trial compares two ways of reconnecting the pancreas after a Whipple surgery for cancer. It tests whether using a special surgical glue (Glubran2) helps reduce leaks and improve healing.
MinyaAges 18–75 - NCT06756217Recruiting
PET scan to check early response to immunotherapy before lung cancer surgery
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06756334RecruitingEarly Phase 1
Comparing Two PET/CT Scans for Prostate Cancer
This study compares two types of PET/CT scans (using different radioactive tracers) to see which one is better at finding prostate cancer, detecting if it has come back, or spotting spread to other parts of the body. You will get both scans so doctors can compare them directly.
Hefei, AnhuiAges 18–90 - NCT06757244RecruitingPhase 2
Dovipa: Immunotherapy and vitamin D with chemo for advanced pancreatic cancer
This trial tests whether combining the immunotherapy dostarlimab with vitamin D3 and standard chemotherapy (mFOLFIRINOX) can help people with stage IV pancreatic cancer. It aims to see if this new approach is safe and effective.
MarseilleAges 18–75 - NCT06758557RecruitingPhase 1/Phase 2
HB0025 for advanced solid tumors
This trial tests a new drug called HB0025 for people with advanced non-small cell lung cancer or endometrial cancer that cannot be removed by surgery. The study aims to see if the drug is safe and effective.
Baoding, HebeiAges 18–75
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 13,110 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.